Royalty Pharma (RPRX) Shares Outstanding (Diluted Average) (2020 - 2026)

Royalty Pharma has disclosed Shares Outstanding (Diluted Average) across 7 years of filings, most recently posting $556.8 million for Q1 2026.

• Shares Outstanding (Diluted Average) for Q1 2026 came in at $556.8 million, down 3.68% year-over-year; the trailing twelve-month figure through Mar 2026 was $556.8 million (down 3.68% YoY), and the FY2025 annual result was $564.5 million, down 4.99% from the prior year.
• Shares Outstanding (Diluted Average) came in at $556.8 million for Q1 2026 at Royalty Pharma, down from $564.5 million in the prior quarter.
• In the past five years, Shares Outstanding (Diluted Average) ranged from a high of $607.3 million in Q1 2023 to a low of $438.0 million in Q4 2022.
• The 5-year median for Shares Outstanding (Diluted Average) is $597.2 million (2024), against an average of $581.6 million.
• Across the five-year window, Shares Outstanding (Diluted Average) soared 37.66% in 2023 and fell 5.59% in 2025, its largest moves.
• Royalty Pharma's Shares Outstanding (Diluted Average) stood at $438.0 million in 2022, then jumped by 37.66% to $602.9 million in 2023, then fell by 1.46% to $594.1 million in 2024, then declined by 4.99% to $564.5 million in 2025, then decreased by 1.35% to $556.8 million in 2026.
• The last three Shares Outstanding (Diluted Average) figures came in at $556.8 million (Q1 2026), $564.5 million (Q4 2025), and $559.6 million (Q3 2025), per Business Quant data.